Targeting immune checkpoints:how to use natural killer cells for fighting against solid tumors  

作　　者：Farhoodeh Ghaedrahmati Nafiseh Esmaeil Maryam Abbaspour 

机构地区：[1]Department of Immunology,School of Medicine,Isfahan University of Medical Sciences,Isfahan,Iran [2]Research Institute for Primordial Prevention of Non-Communicable Disease,Isfahan University of Medical Sciences,Isfahan,Iran [3]Department of Pharmaceutical Biotechnology,Faculty of Pharmacy,Isfahan University of Medical Sciences,Isfahan,Iran

出　　处：《Cancer Communications》2023年第2期177-213,共37页癌症通讯（英文）

基　　金：This work was supported by Isfahan University of Medical Sciences,Isfahan,Iran(grant No.140170).

摘　　要：Natural killer(NK)cells are unique innate immune cells that mediate antiviral and anti-tumor responses.Thus,they might hold great potential for cancer immunotherapy.NK cell adoptive immunotherapy in humans has shown modest efficacy.In particular,it has failed to demonstrate therapeutic efficiency in the treatment of solid tumors,possibly due in part to the immunosuppressive tumor microenvironment(TME),which reduces NK cell immunotherapy’s efficiencies.It is known that immune checkpoints play a prominent role in creating an immunosuppressive TME,leading to NK cell exhaustion and tumor immune escape.Therefore,NK cells must be reversed from their dysfunctional status and increased in their effector roles in order to improve the efficiency of cancer immunotherapy.Blockade of immune checkpoints can not only rescue NK cells from exhaustion but also augment their robust anti-tumor activity.In this review,we discussed immune checkpoint blockade strategies with a focus on chimeric antigen receptor(CAR)-NK cells to redirect NK cells to cancer cells in the treatment of solid tumors.

关 键 词：natural killer cell immune checkpoint chimeric antigen receptor-natural killer cell IMMUNOTHERAPY tumor 

分 类 号：R730.3[医药卫生—肿瘤]